HealthcareLarge capRs 28,361 crRs 138.7 cr traded a dayHealthcarePharmaceuticals
Close on 2026-08-21
213.67
−1.38%
52-week range96% of the way up
133.27216.66
Market cap
28,361 cr
Revenue YoY
+17.4%
Q1 FY27
Net margin
-3.1%
+1.2pt vs a year ago
Growth trend
+17.5pt
vs last quarter’s YoY
1 month
+18.2%
Below 52w high
1.4%
RSI (14)
66
Daily swing
3.6%
average true range
Volume
0.6×
vs 20-day average
Traded
Rs 139 cr
median day
Close200-day averageMaterial filing
260 sessions · hover for the filing behind a move
1 week
+3.40%
1 month
+18.16%
3 months
+19.46%
6 months
+31.55%
1 year
+14.44%
The read
written from the numbers on this page
The evidence leans constructive8 supporting, 0 against, 0 worth knowing
Supporting
trading 26% above its 200-day average
sitting at 96% of its 52-week range, with little overhead supply from trapped buyers
up 14% over twelve months
matches stretched far above trend, which has beaten the market by +0.82 points over 20 sessions across 27,715 past signals
2 of the scans it matches have a positive measured record
5 independent kinds of evidence agree today, which is uncommon
revenue grew 17% year on year in the quarter ending 2026-06-30
net margin has widened from -4.9% to -3.1% across four quarters
Against
nothing the data supports either way
Worth knowing
nothing the data supports either way
PPLPHARMA sits in Healthcare, Pharmaceuticals — worth checking whether the whole group is moving together or whether this name is doing it alone.
What would change this read: a close below 169, its 200-day average; a failure to hold the top of its 52-week range.
Assembled automatically from the figures on this page — the scans matched, their measured record, the filed financials, the derivatives positioning and the peer comparison. It is not a recommendation, no one has spoken to the company, and every claim above can be checked against a number further down this page.
What is working, what is not
read from the filings, with the figure behind every line
Working2
Revenue +17.4% year on year, Rs 1,934 cr to Rs 2,270 cr.
+17.4%Rs 1,934 crRs 2,270 cr
Net margin moved from -4.2% to -3.1%.
-4.2%-3.1%
Needs watching
Nothing in the filings stands out either way.
Every figure here is computed from the company’s own filings. The wording is generated directly from the figures.
How it has performed
price return over each window, measured against zero
What the scans say today
6 of 47 matched on 2026-08-21
PPLPHARMA matches 6 of the 47 scans today, across 5 different kinds of evidence. Three or more independent families agreeing is uncommon — it is the same test the shortlist on every page uses.
Return on capital uses profit before tax over equity plus borrowings. The textbook version adds finance costs back; those are not tagged reliably in quarterly filings, so this understates the ratio for a heavily borrowed company rather than flattering it. Balance sheets are filed half-yearly, so these can be up to six months behind the profit figures above.
Valuation against its own history
330 sessions since 2025-05-14
193×
median 248×
300×
now 289×
PPLPHARMA trades at 289× trailing earnings, above its median of 248× over this window — 16% more expensive than usual. The band runs from the 5th to the 95th percentile, so single-day spikes do not set the edges.
This window is short by the standards of valuation history — it begins where four quarters of filed earnings first exist. A stock can look cheap against two years and expensive against ten.
M&A filings were typically +0.23pt vs the market over the next 5 sessions (n=981) · Analyst call filings were typically +0.14pt vs the market over the next 5 sessions (n=3,352) · Other filing filings were typically -0.08pt vs the market over the next 5 sessions (n=12,093)
The business
from the company’s filed results
Everything below is taken from the company’s own quarterly filing with the exchange — the XBRL document it submitted, not a vendor’s summary of it. Figures in rupees crore.
RevenueNet profit, drawn inside its revenue barNet margin, own scale belowrupees crore, per quarter as filed. Revenue bars start at zero.
Going for it
revenue grew 17% against the same quarter a year earlier
revenue rose in 3 of the last 4 quarters
Going against it
profit dropped 15% year on year
net margin narrowed from -0.3% to -3.1%
the company has not been profitable over the last four filed quarters
Quarter-by-quarter numbers, as filed
Quarter
Revenue
Profit before tax
Net profit
EPS
Net margin
Q1 FY27
2026-06-30 · consolidated
2,270
-27
-69
—
-3.1%
Q4 FY26
2026-03-31 · consolidated
2,752
29
-9
—
-0.3%
Q3 FY26
2025-12-31 · consolidated
2,140
-104
-136
—
-6.4%
Q2 FY26
2025-09-30 · consolidated
2,044
-61
-99
—
-4.9%
Q1 FY26
2025-06-30 · consolidated
1,934
-98
-82
—
-4.2%
Q4 FY25
2025-03-31 · consolidated
2,754
257
154
1.16
5.6%
Quarterly filings are unaudited unless stated. Consolidated figures are used where the company files both. A single quarter is a noisy thing — the trend across the column is worth more than the top row.
Where the price stands
the same figures every scan on this site is computed from
Trend
Distance from the averages traders watch. Above all of them is a bull phase; below the 200-day is the line most investors use to say otherwise.
Versus 50-day average+15.5%
Versus 200-day average+26.3%
Below 52-week high-1.4%
Above 52-week low+60.3%
Momentum
How hard it has been pushed lately. Above 70 on RSI is stretched, below 30 is washed out — neither is a signal on its own.
RSI (14)65.7
Higher closes in last 52 of 5
Six-month return+31.55%
Risk and liquidity
What a position costs to hold and to exit. Position sizing starts with the daily swing, not with conviction.
largest twelve by market capitalisation. Market cap and P/E need filed financials, so blanks are companies whose filings have not been read yet
Recent sessions
what this stock has matched since the engine went live
This is the live record, not the backtest — the scans this stock actually appeared in on each stored session. A name that keeps reappearing is in a persistent condition; a one-day appearance usually is not.
Session
Scans
Which
2026-08-20
3
Bullish engulfing, Closed at the very top of its range, Closed at the day's high
2026-08-18
2
Bullish engulfing, Closed at the very top of its range